Takeda Pharmaceutical Co Ltd
TAKHealthcare|Drug Manufacturers - Specialty & Generic|Japan
$16.56
-0.05 (-0.30%)
DCF (FCF)
$23.41
Upcoming Data Readouts (48)
Jul 2026
Est. completion
Jul 2026
Est. completion
Cytomegalovirus (CMV)
A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
NCT06213974n=10
Aug 2026
Est. completion
Lysosomal Disease
A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico
NCT07494058n=222
Sep 2026
Est. completion
P2Crohn's Disease
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461n=268
Oct 2026
Est. completion
P3Narcolepsy Type 1 (NT1)
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720n=88
Oct 2026
Est. completion
Oct 2026
Est. completion
P3Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502n=354
Dec 2026
Est. completion
P2Myeloma, Multiple
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
NCT04009109n=79
Dec 2026
Est. completion
Dec 2026
Est. completion
P3Cytomegalovirus (CMV)
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
NCT06439342n=20
Dec 2026
Est. completion
Hereditary Angioedema (HAE)
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
NCT05469789n=50
Jan 2027
Est. completion
P2Colon Cancer
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
NCT07011576n=60
Jan 2027
Est. completion
Feb 2027
Est. completion
Multiple Myeloma
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
NCT05879757n=75
Mar 2027
Est. completion
Apr 2027
Est. completion
Non-small Cell Lung Cancer (NSCLC)
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
NCT05735327n=50
May 2027
Est. completion
P3Psoriatic Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483n=1,088
Jun 2027
Est. completion
P3Crohn's Disease
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910n=396
Jun 2027
Est. completion
P4Crohn's Disease
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754n=100
Jul 2027
Est. completion
Colorectal Cancer
An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer
NCT05030493n=787
Awaiting Results (6)
Trials past primary completion date but still active — data readout may be imminent.
Jul 2026
P1
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
NCT04464200Mar 2026
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
NCT07123350Dec 2024
A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil
NCT05626088Jun 2024
P2
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
NCT05020015Mar 2024
VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)
NCT05158517Aug 2022
P3
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326